Ropeginterferon Alfa-2b
Besremi is a prescription brand-name medication containing the active ingredient ropeginterferon alfa-2b, used to treat polycythemia vera (a blood disorder where the bone marrow produces too many red blood cells) in adults. It is a long-acting interferon administered by subcutaneous injection, typically every 2 to 4 weeks. This medication helps reduce the need for phlebotomy (blood removal) and may improve disease-related symptoms.
Besremi is a long-acting interferon injection used to treat polycythemia vera in adults by reducing excessive red blood cell production.
Key facts at a glance
- RxNorm
- 2587066
- Generic
- Besremi
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Besremi is FDA-approved for the treatment of polycythemia vera in adults, a chronic blood cancer characterized by overproduction of red blood cells. It is used to reduce the risk of thrombotic events (blood clots) and may decrease the need for therapeutic phlebotomy.
Besremi contains ropeginterferon alfa-2b, a monoPEGylated type I interferon that binds to interferon receptors on cell surfaces. While the exact mechanism in polycythemia vera is not fully established, it is believed to modulate cell proliferation, apoptosis, and immune function, ultimately reducing abnormal blood cell production.
Besremi carries a boxed warning for serious psychiatric, autoimmune, ischemic, and infectious disorders. Common side effects may include flu-like symptoms, fatigue, joint pain, and liver enzyme elevations. It is contraindicated in patients with severe psychiatric conditions or autoimmune disorders. Regular monitoring of blood counts and liver function is required during treatment. The medication is administered as a subcutaneous injection and should only be prescribed by healthcare providers experienced in managing polycythemia vera.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed September 3, 2026. · Read our editorial policy